Sandoz Canada
A Canadian division focused on development, manufacture, and commercialization of generic and biosimilar medicines, with capabilities in quality systems, supply chain management, product launches, medical information, and community engagement through grants and sponsorships.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Generic small-molecule medicines portfolio
A portfolio of approved generic medicines across multiple therapeutic categories marketed in Canada.
Biosimilars portfolio
A portfolio of biosimilar medicines intended to offer alternatives to reference biologics in therapeutic areas covered in Canada.
Specialty medicines portfolio
Products categorized as specialty medicines managed alongside generics and biosimilars.
Sitagliptin and sitagliptin–metformin generic products
Recently launched generic versions of sitagliptin and a sitagliptin–metformin combination for glucose management.
Generic small-molecule medicines portfolio
A portfolio of approved generic medicines across multiple therapeutic categories marketed in Canada.
Biosimilars portfolio
A portfolio of biosimilar medicines intended to offer alternatives to reference biologics in therapeutic areas covered in Canada.
Specialty medicines portfolio
Products categorized as specialty medicines managed alongside generics and biosimilars.
Sitagliptin and sitagliptin–metformin generic products
Recently launched generic versions of sitagliptin and a sitagliptin–metformin combination for glucose management.
Services
Provides a medical inquiry channel for healthcare professionals and patients to request clinical and safety information about marketed medicines.
Administration of corporate philanthropy and community sponsorships in Canada.
National contact and office network to support commercial operations and customer service within Canada.
Provides a medical inquiry channel for healthcare professionals and patients to request clinical and safety information about marketed medicines.
Administration of corporate philanthropy and community sponsorships in Canada.
National contact and office network to support commercial operations and customer service within Canada.
Expertise Areas
- Generic medicine development and commercialization
- Biosimilar development and market access
- GMP manufacturing and quality assurance
- Supply chain and distribution logistics
Key Technologies
- GMP manufacturing
- Biologics/biopharmaceutical manufacturing
- Small-molecule formulation
- Analytical chemistry and impurity testing
News & Updates
Public communication regarding recall actions for ranitidine medicines due to detected quality concerns.
Public communication regarding recall actions related to valsartan products due to quality/contaminant issues.
Media release announcing expansion of the generic product portfolio in Canada.
Media release announcing the launch of sitagliptin and sitagliptin–metformin generic products.
Media release describing support for a provincial policy change to cover biosimilars to improve access and cost savings.
Public communication regarding recall actions for ranitidine medicines due to detected quality concerns.
Public communication regarding recall actions related to valsartan products due to quality/contaminant issues.
Media release announcing expansion of the generic product portfolio in Canada.
Media release announcing the launch of sitagliptin and sitagliptin–metformin generic products.
Media release describing support for a provincial policy change to cover biosimilars to improve access and cost savings.